842971-64-6 Usage
Uses
Used in Pharmaceutical Research and Development:
1-(6-Ethyl-thieno[2,3-d]pyrimidin-4-yl)-piperidine-4-carboxylic acid is used as a chemical compound in pharmaceutical research and development for its potential medicinal properties. 1-(6-ETHYL-THIENO[2,3-D]PYRIMIDIN-4-YL)-PIPERIDINE-4-CARBOXYLIC ACID's unique structure, which includes a piperidine ring and a carboxylic acid group, along with the presence of a thieno[2,3-d]pyrimidin-4-yl group with an ethyl substituent, suggests that it may have therapeutic applications. However, further research and clinical trials are required to confirm its efficacy and safety in various medical applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(6-Ethyl-thieno[2,3-d]pyrimidin-4-yl)-piperidine-4-carboxylic acid is used as a starting material or a structural component in the design and synthesis of new drugs. Its unique chemical features may allow for the development of novel therapeutic agents with improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects. Further exploration of its chemical reactivity and potential interactions with biological targets is essential for optimizing its use in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 842971-64-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,2,9,7 and 1 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 842971-64:
(8*8)+(7*4)+(6*2)+(5*9)+(4*7)+(3*1)+(2*6)+(1*4)=196
196 % 10 = 6
So 842971-64-6 is a valid CAS Registry Number.
842971-64-6Relevant academic research and scientific papers
IRAK INHIBITORS AND USES THEREOF
-
Page/Page column 185-187, (2012/07/28)
The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
